Examining NSCLC responses to durvalumab monotherapy

PD-L2 expression and its relevance to anti-PD-1 therapy in cancer

NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs

RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours

Circulating levels of tumour DNA in plasma may help monitor treatment response and resistance in CLL

Cytogenetic and proteomic prognostic markers of CLL

Predicting progression and survival in CLL

Expert panel discussion: The best of iwCLL 2015

Targeting the NEDD8-activating enzyme to induce apoptosis in CLL cells

High remission rates for new CLL treatment

CLL from a patient and physician perspective

Harmonisation of CLL diagnosis and detection of residual disease monitoring by flow cytometry